ZENTIVA S.A.
Zentiva S.A. engages in the production and marketing of preparations and medicines for human use in Romania and internationally. The company develops pharmaceutical products in various therapeutic areas, such as cardiovascular diseases, anti-inflammatory and pain-relieving medications, urologists, blood diseases, gastrointestinal and metabolic disorders, central nervous system, infections, respir… Read more
ZENTIVA S.A. (SCD) - Net Assets
Latest net assets as of March 2025: RON1.50 Billion RON
Based on the latest financial reports, ZENTIVA S.A. (SCD) has net assets worth RON1.50 Billion RON as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (RON1.85 Billion) and total liabilities (RON350.60 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | RON1.50 Billion |
| % of Total Assets | 81.02% |
| Annual Growth Rate | 15.47% |
| 5-Year Change | 83.56% |
| 10-Year Change | N/A |
| Growth Volatility | 3.81 |
ZENTIVA S.A. - Net Assets Trend (2019–2024)
This chart illustrates how ZENTIVA S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for ZENTIVA S.A. (2019–2024)
The table below shows the annual net assets of ZENTIVA S.A. from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-09-30 | RON1.44 Billion | +21.01% |
| 2023-09-30 | RON1.19 Billion | +19.20% |
| 2022-09-30 | RON999.35 Million | +12.19% |
| 2021-09-30 | RON890.77 Million | +13.42% |
| 2020-09-30 | RON785.36 Million | +11.88% |
| 2019-09-30 | RON702.00 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to ZENTIVA S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 139.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (September 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | RON1.08 Billion | 75.02% |
| Other Components | RON360.10 Million | 24.98% |
| Total Equity | RON1.44 Billion | 100.00% |
ZENTIVA S.A. Competitors by Market Cap
The table below lists competitors of ZENTIVA S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Frigoglass S.A.I.C.
AT:FRIGO
|
$26.35 Million |
|
S.S. Lazio S.p.A
F:LZO1
|
$26.36 Million |
|
AYM Syntex Limited
NSE:AYMSYNTEX
|
$26.36 Million |
|
Chosun Refractories Co Ltd
KO:000480
|
$26.36 Million |
|
Abitibi Metals Corp
OTCQB:AMQFF
|
$26.34 Million |
|
kenturn Nano Tec Co Ltd
TWO:4561
|
$26.34 Million |
|
Zhixin Group Holding Limited
PINK:ZHIXF
|
$26.34 Million |
|
374Water Inc. Common Stock
NASDAQ:SCWO
|
$26.34 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ZENTIVA S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,191,262,465 to 1,441,585,389, a change of 250,322,924 (21.0%).
- Net income of 250,510,124 contributed positively to equity growth.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | RON250.51 Million | +17.38% |
| Other Changes | RON-187.20K | -0.01% |
| Total Change | RON- | 21.01% |
Book Value vs Market Value Analysis
This analysis compares ZENTIVA S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.19x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 4.49x to 2.19x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-09-30 | RON1.01 | RON4.52 | x |
| 2020-09-30 | RON1.13 | RON4.52 | x |
| 2021-09-30 | RON1.28 | RON4.52 | x |
| 2022-09-30 | RON1.43 | RON4.52 | x |
| 2023-09-30 | RON1.71 | RON4.52 | x |
| 2024-09-30 | RON2.07 | RON4.52 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ZENTIVA S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 17.38%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.49%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 1.20x
- Recent ROE (17.38%) is above the historical average (11.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 6.23% | 7.30% | 0.59x | 1.45x | RON-26.45 Million |
| 2020 | 8.36% | 11.76% | 0.54x | 1.32x | RON-12.90 Million |
| 2021 | 11.87% | 14.90% | 0.68x | 1.18x | RON16.67 Million |
| 2022 | 9.95% | 13.09% | 0.63x | 1.21x | RON-470.25K |
| 2023 | 16.17% | 20.20% | 0.64x | 1.26x | RON73.49 Million |
| 2024 | 17.38% | 22.49% | 0.64x | 1.20x | RON106.35 Million |
Industry Comparison
This section compares ZENTIVA S.A.'s net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $552,097,226
- Average return on equity (ROE) among peers: 14.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ZENTIVA S.A. (SCD) | RON1.50 Billion | 6.23% | 0.23x | $26.35 Million |
| Antibiotice Ia (ATB) | $846.96 Million | 9.57% | 0.35x | $94.81 Million |
| Biofarm Bucure (BIO) | $257.23 Million | 19.78% | 0.35x | $128.28 Million |